Allurion announces initial results on the combination of the allurion program with low-dose glp-1 therapy to optimize muscle mass and glp-1 adherence

Natick, mass.--(business wire)---- $alur--allurion technologies, inc. (“allurion” or the “company”) (nyse: alur), a company dedicated to ending obesity, today announced initial results on the combination of the allurion program with low-dose glp-1 therapy to optimize muscle mass and glp-1 adherence. 52 patients treated with the allurion balloon were started on 0.25mg semaglutide after completing their first month of balloon therapy. the dose of semaglutide was increased to no greater than 1.0mg over the.
ALUR Ratings Summary
ALUR Quant Ranking